go back to reference Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte RT, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D’Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S, Bidard F, Pistilli B, Dalenc F, Bachelot T, De La Motte RT, Sabatier R, Dubot C, Frenel J, Ferrero J, Ladoire S, Levy C, Mouret-reynier M, Hardy-bessard A, Lortholary A, Grenier J, Chakiba C, Stefani L, Soulie P, Jacquin J, Plaza JE, Clatot F, Teixeira L, D’hondt V, Vegas H, Derbel O, Garnier Tixidre C, Delbaldo C, Moreau L, Cheneau C, Paitel J, Bernard-marty C, Spaeth D, Genet D, Moullet I, Bonichon-lamichhane N, Deiana L, Greilsamer C, Venat-bouvet L, Delecroix V, Melis A, Orfeuvre H, Nguyen S, Legouffe E, Zannetti A, Le Scodan R, Dohollou N, Dalivoust P, Arsene O, Marques N, Petit T, Mollon D, Dauba J, Bonnin N, Morvan F, Gardner M, Marti A, Levache C, Lachaier E, Achille M, Valmar C, Bouaita R, Medioni J, Foa C, Bernard-marty C, Del Piano F, Gozy M, Escande A, Leduc N, Lucas B, Mille D, Ammarguellat H, Najem A, Trouboul F, Barthelemy P, Desclos H, Mayeur D, Lorchel F, Guinet F, Laurenty A, Boudrant A, Gisserot O, Alleaume C, De Gramont A (2022) Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 23:1367–1377. https://doi.org/10.1016/S1470-2045(22)00555-1CrossRefPubMed
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte RT, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D’Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S, Bidard F, Pistilli B, Dalenc F, Bachelot T, De La Motte RT, Sabatier R, Dubot C, Frenel J, Ferrero J, Ladoire S, Levy C, Mouret-reynier M, Hardy-bessard A, Lortholary A, Grenier J, Chakiba C, Stefani L, Soulie P, Jacquin J, Plaza JE, Clatot F, Teixeira L, D’hondt V, Vegas H, Derbel O, Garnier Tixidre C, Delbaldo C, Moreau L, Cheneau C, Paitel J, Bernard-marty C, Spaeth D, Genet D, Moullet I, Bonichon-lamichhane N, Deiana L, Greilsamer C, Venat-bouvet L, Delecroix V, Melis A, Orfeuvre H, Nguyen S, Legouffe E, Zannetti A, Le Scodan R, Dohollou N, Dalivoust P, Arsene O, Marques N, Petit T, Mollon D, Dauba J, Bonnin N, Morvan F, Gardner M, Marti A, Levache C, Lachaier E, Achille M, Valmar C, Bouaita R, Medioni J, Foa C, Bernard-marty C, Del Piano F, Gozy M, Escande A, Leduc N, Lucas B, Mille D, Ammarguellat H, Najem A, Trouboul F, Barthelemy P, Desclos H, Mayeur D, Lorchel F, Guinet F, Laurenty A, Boudrant A, Gisserot O, Alleaume C, De Gramont A (2022) Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 23:1367–1377.
https://doi.org/10.1016/S1470-2045(22)00555-1CrossRefPubMed